On the inhibition of histone deacetylase 8

被引:74
|
作者
Estiu, Guillermina [1 ,2 ]
West, Nathan [3 ,4 ,5 ]
Mazitschek, Ralph [3 ,4 ,6 ]
Greenberg, Edward [3 ,4 ,5 ]
Bradner, James E. [3 ,4 ,5 ]
Wiest, Olaf [1 ,2 ]
机构
[1] Univ Notre Dame, Walther Canc Res Ctr, Notre Dame, IN 46556 USA
[2] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA
[3] Harvard Univ, Broad Inst, Cambridge, MA 02142 USA
[4] MIT, Cambridge, MA 02142 USA
[5] Dana Farber Canc Inst, Div Hematol Neoplasia, Boston, MA 02115 USA
[6] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA
关键词
HDAC; Computational drug design; Molecular dynamics; Enzymology; CATION-PI INTERACTIONS; MOLECULAR-DYNAMICS; CLASS-II; CRYSTAL-STRUCTURE; INTERNAL CAVITY; HUMAN HDAC8; SUBSTRATE; PROTEIN; DESIGN; CANCER;
D O I
10.1016/j.bmc.2010.03.080
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone deacetylases are key regulators of gene expression and have recently emerged as important therapeutic targets for cancer and a growing number of non-malignant diseases. Many widely studied inhibitors of HDACs such as SAHA are thought to have low selectivity within or between the human HDAC isoform classes. Using an isoform-selective assay, we have shown that a number of the known inhibitors have in fact a low activity against HDAC8. Based on the wealth of structural information available for human HDAC8, we use a combination of docking and molecular dynamics simulations to determine the structural origin of the experimental results. A close relationship is found between the activity and the high surface malleability of HDAC8. These results provide a rationale for the recently described 'linkerless' HDAC8 selective inhibitors and design criteria for HDAC8 selective inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4103 / 4110
页数:8
相关论文
共 50 条
  • [41] Histone deacetylase inhibition blunts pathological cardiac hypertrophy
    Kong, YL
    Berenji, K
    Tannous, P
    Rothermel, BA
    Hill, JA
    CIRCULATION, 2004, 110 (17) : 24 - 24
  • [42] The inhibition of histone deacetylase exacerbates atherosclerosis in hyperlipidemic mice
    Choi, JH
    Nam, KH
    Kim, J
    Ryu, YH
    Baek, MW
    Kwon, HJ
    Kim, DY
    Oh, GT
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 332 - 332
  • [43] Inhibition of histone deacetylase1 induces autophagy
    Oh, Meeyeon
    Choi, In-Kwon
    Kwon, Ho Jeong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 369 (04) : 1179 - 1183
  • [44] Analysis of macrophage function and histone deacetylase inhibition in neuroblastoma
    Brumfield, Gabrielle L.
    Knoche, Shelby M.
    Larson, Alaina C.
    Poelaert, Brittany J.
    Goetz, Benjamin T.
    Pandey, Poomy
    Coulter, Donald W.
    Solheim, Joyce C.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [45] Selective histone deacetylase inhibition augments melanoma immunotherapy
    Laino, Andressa Sodre
    Woods, David Michael
    Sarnaik, Amod
    Quayle, Steven
    Jones, Simon S.
    Sotomayor, Eduardo M.
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Histone deacetylase inhibition: a novel approach to cancer treatment
    B D Cheson
    British Journal of Cancer, 2006, 95 : S1 - S1
  • [47] A novel mechanism of chemoprotection by sulforaphane: Inhibition of histone deacetylase
    Myzak, MC
    Karplus, PA
    Chung, FL
    Dashwood, RH
    CANCER RESEARCH, 2004, 64 (16) : 5767 - 5774
  • [48] Targeted inhibition of histone deacetylase 6 in inflammatory diseases
    Ran, Jie
    Zhou, Jun
    THORACIC CANCER, 2019, 10 (03) : 405 - 412
  • [49] Histone Deacetylase Inhibition:An Important Mechanism in the Treatment of Lymphoma
    Shan-qi Guo
    Yi-zhuo Zhang
    Cancer Biology & Medicine, 2012, 9 (02) : 85 - 89
  • [50] Histone deacetylase inhibition: a novel approach to cancer treatment
    Cheson, B. D.
    BRITISH JOURNAL OF CANCER, 2006, 95 (Suppl 1) : S1 - S1